These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24650799)

  • 1. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
    Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
    Choudhary GS; Al-Harbi S; Mazumder S; Hill BT; Smith MR; Bodo J; Hsi ED; Almasan A
    Cell Death Dis; 2015 Jan; 6(1):e1593. PubMed ID: 25590803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.
    Mazumder S; Choudhary GS; Al-Harbi S; Almasan A
    Cancer Res; 2012 Jun; 72(12):3069-79. PubMed ID: 22525702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer.
    Li H; Liu L; Chang H; Zou Z; Xing D
    Cell Death Dis; 2018 Jan; 9(2):137. PubMed ID: 29374168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.
    Spender LC; Inman GJ
    Mol Cancer Res; 2012 Mar; 10(3):347-59. PubMed ID: 22241218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABT-737 induces Bim expression via JNK signaling pathway and its effect on the radiation sensitivity of HeLa cells.
    Wang H; Yang YB; Shen HM; Gu J; Li T; Li XM
    PLoS One; 2012; 7(12):e52483. PubMed ID: 23285061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737.
    Potter DS; Kelly P; Denneny O; Juvin V; Stephens LR; Dive C; Morrow CJ
    Neoplasia; 2014 Feb; 16(2):147-57. PubMed ID: 24709422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.
    He L; Torres-Lockhart K; Forster N; Ramakrishnan S; Greninger P; Garnett MJ; McDermott U; Rothenberg SM; Benes CH; Ellisen LW
    Cancer Discov; 2013 Mar; 3(3):324-37. PubMed ID: 23274910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation.
    Bonnefond ML; Lambert B; Giffard F; Abeilard E; Brotin E; Louis MH; Gueye MS; Gauduchon P; Poulain L; N'Diaye M
    Apoptosis; 2015 Apr; 20(4):535-50. PubMed ID: 25627260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
    Faber AC; Coffee EM; Costa C; Dastur A; Ebi H; Hata AN; Yeo AT; Edelman EJ; Song Y; Tam AT; Boisvert JL; Milano RJ; Roper J; Kodack DP; Jain RK; Corcoran RB; Rivera MN; Ramaswamy S; Hung KE; Benes CH; Engelman JA
    Cancer Discov; 2014 Jan; 4(1):42-52. PubMed ID: 24163374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.
    Albershardt TC; Salerni BL; Soderquist RS; Bates DJ; Pletnev AA; Kisselev AF; Eastman A
    J Biol Chem; 2011 Jul; 286(28):24882-95. PubMed ID: 21628457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined MEK and BCL-2/X
    Iavarone C; Zervantonakis IK; Selfors LM; Palakurthi S; Liu JF; Drapkin R; Matulonis UA; Hallberg D; Velculescu VE; Leverson JD; Sampath D; Mills GB; Brugge JS
    Mol Cancer Ther; 2019 Mar; 18(3):642-655. PubMed ID: 30679390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors.
    Korfi K; Smith M; Swan J; Somervaille TC; Dhomen N; Marais R
    Cell Death Dis; 2016 Apr; 7(4):e2177. PubMed ID: 27054332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström macroglobulinemia.
    Gaudette BT; Dwivedi B; Chitta KS; Poulain S; Powell D; Vertino P; Leleu X; Lonial S; Chanan-Khan AA; Kowalski J; Boise LH
    Oncogene; 2016 Jan; 35(4):479-90. PubMed ID: 25893290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2.
    Yue W; Zheng X; Lin Y; Yang CS; Xu Q; Carpizo D; Huang H; DiPaola RS; Tan XL
    Oncotarget; 2015 Aug; 6(25):21208-24. PubMed ID: 26056043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically defining the mechanism of Puma- and Bim-induced apoptosis.
    Garrison SP; Phillips DC; Jeffers JR; Chipuk JE; Parsons MJ; Rehg JE; Opferman JT; Green DR; Zambetti GP
    Cell Death Differ; 2012 Apr; 19(4):642-9. PubMed ID: 22015606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins.
    Alcon C; Gómez Tejeda Zañudo J; Albert R; Wagle N; Scaltriti M; Letai A; Samitier J; Montero J
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53.
    Yang MC; Lin RW; Huang SB; Huang SY; Chen WJ; Wang S; Hong YR; Wang C
    Cell Cycle; 2016; 15(3):394-402. PubMed ID: 26694174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study.
    Rajule R; Bryant VC; Lopez H; Luo X; Natarajan A
    Bioorg Med Chem; 2012 Apr; 20(7):2227-34. PubMed ID: 22386982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines.
    Lian BSX; Yek AEH; Shuvas H; Abdul Rahman SF; Muniandy K; Mohana-Kumaran N
    BMC Res Notes; 2018 Mar; 11(1):197. PubMed ID: 29580266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.